Cantor Fitzgerald Has Positive View of AUPH FY2026 Earnings

Key Points

• Analysts at Cantor Fitzgerald have raised their FY2026 earnings per share (EPS) estimate for Aurinia Pharmaceuticals to $0.74, up from a previous forecast of $0.64.
• Aurinia Pharmaceuticals reported $0.16 EPS for the latest quarter, which was below the consensus estimate of $0.17, despite having a revenue of $70.01 million exceeding expectations.
• HC Wainwright reaffirmed a "buy" rating for Aurinia with a price target of $17.00, while Royal Bank of Canada increased its price target from $8.00 to $9.00.

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Free Report) TSE: AUP - Equities research analysts at Cantor Fitzgerald upped their FY2026 earnings per share (EPS) estimates for shares of Aurinia Pharmaceuticals in a report released on Friday, August 1st. Cantor Fitzgerald analyst O. Brayer now expects that the biotechnology company will post earnings of $0.74 per share for the year, up from their prior forecast of $0.64. The consensus estimate for Aurinia Pharmaceuticals' current full-year earnings is $0.11 per share.

A number of other research analysts have also weighed in on AUPH. Royal Bank Of Canada lifted their target price on Aurinia Pharmaceuticals from $8.00 to $9.00 and gave the company an "outperform" rating in a report on Friday, August 1st. HC Wainwright reaffirmed a "buy" rating and set a $17.00 target price on shares of Aurinia Pharmaceuticals in a report on Wednesday, July 30th.

Aurinia Pharmaceuticals Price Performance

AUPH stock traded down $0.09 during mid-day trading on Monday, reaching $11.61. 3,849,429 shares of the company traded hands, compared to its average volume of 1,589,543. The company has a debt-to-equity ratio of 0.18, a current ratio of 5.23 and a quick ratio of 4.63. The company has a market capitalization of $1.53 billion, a P/E ratio of 27.00 and a beta of 1.23. Aurinia Pharmaceuticals has a 52-week low of $5.25 and a 52-week high of $11.80. The company has a fifty day moving average price of $8.49 and a 200-day moving average price of $8.18.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last announced its quarterly earnings data on Thursday, July 31st. The biotechnology company reported $0.16 earnings per share for the quarter, missing the consensus estimate of $0.17 by ($0.01). Aurinia Pharmaceuticals had a return on equity of 20.06% and a net margin of 23.31%. The firm had revenue of $70.01 million during the quarter, compared to analysts' expectations of $64.27 million.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. GF Fund Management CO. LTD. bought a new stake in Aurinia Pharmaceuticals in the 4th quarter worth approximately $27,000. Tower Research Capital LLC TRC lifted its position in Aurinia Pharmaceuticals by 368.5% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,350 shares of the biotechnology company's stock worth $30,000 after buying an additional 2,635 shares during the last quarter. Vermillion & White Wealth Management Group LLC bought a new stake in Aurinia Pharmaceuticals in the 4th quarter worth approximately $31,000. GAMMA Investing LLC lifted its position in Aurinia Pharmaceuticals by 56.1% in the 1st quarter. GAMMA Investing LLC now owns 4,852 shares of the biotechnology company's stock worth $39,000 after buying an additional 1,744 shares during the last quarter. Finally, MAI Capital Management bought a new stake in Aurinia Pharmaceuticals in the 1st quarter worth approximately $39,000. Hedge funds and other institutional investors own 36.83% of the company's stock.

Insider Activity at Aurinia Pharmaceuticals

In other Aurinia Pharmaceuticals news, Director Kevin Tang acquired 1,000,000 shares of the business's stock in a transaction dated Friday, August 1st. The stock was bought at an average price of $10.12 per share, with a total value of $10,120,000.00. Following the completion of the acquisition, the director owned 11,029,500 shares of the company's stock, valued at $111,618,540. This trade represents a 9.97% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders bought a total of 1,300,000 shares of company stock worth $13,590,000 over the last ninety days. 12.20% of the stock is currently owned by insiders.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.